Trendlyne Blog: , Latest on stock market and finance in India and the world.

Marico Ltd.

10 May 2025

752.40

-0.63%

Marico: What should investors do

Business Line

Low margin of safety, courtesy of premium valuation, dims all other positives

Marico Ltd. has an average target of 842.90 from 10 brokers.

Zydus Wellness Ltd.

09 May 2025

404.25

3.95%

Zydus gets USFDA approval for generic drug to treat multiple sclerosis

Business Standard

Zydus Lifesciences on Friday said it has received approval from the US health regulator to market a generic medication to treat multiple sclerosis. The company has received approval from the US Food and Drug Administration (USFDA) for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL, single-dose prefilled syringes. The company's product is the generic version of Copaxone which is indicated for the treatment of relapsing forms of Multiple Sclerosis (MS). Zydus said the product, developed in collaboration with Chemi S.p.A., will be manufactured entirely in Europe. "This approval underscores Zydus' leadership in bringing complex, differentiated generics to market, reinforcing our commitment to providing a comprehensive range of therapeutic choices for patients," Zydus Lifesciences MD Sharvil Patel said. As per IQVIA MAT data, Glatiramer Acetate Injection had annual sales of USD 719 million in the US market. Shares of Zydus Lifesciences were trading 0.48 per cent up at Rs 876 apie

Zydus Wellness Ltd.'s price crossed above 30Day SMA today

Britannia Industries Ltd.

09 May 2025

5808.50

0.37%

Britannia Share Price Advances After Q4 Revenue, Profit Growth

NDTV Profit

Britannia Industries also recommended a final dividend of Rs 75 per share.

Number of FII/FPI investors increased from 940 to 971 in Dec 2025 qtr.

Britannia Q4FY25 net profit rises 4% YoY to 559 cr

Business Line | 09 May 2025 2 more

Dabur India Ltd.

08 May 2025

453.50

-1.27%

Dabur to drop underperforming tea, diapers; focus on Qcommerce for growth

Business Standard

Homegrown FMCG major Dabur India will exit categories such as tea, adult and baby diapers, and sanitising products as part of rationalisation of its underperforming products, said CEO Mohit Malhotra. The company, aiming "to achieve sustainable double-digit CAGR by FY28 in both topline and bottomline" has renewed its strategy focus, building on its core strengths, he added. Dabur is going for "rationalisation of underperforming products and SKUS in order to release capital for bigger bets. A few examples of these are Vedic tea, adult & baby diapers and Dabur Vita," said Malhotra during the investors' call. These segments contribute less than 1 per cent to Dabur's revenue, which stood at Rs 13,113.19 crore in FY25. "So we will get out of these categories and focus on big, bold equities which we have identified, and the core portfolio is where we will invest," said Malhotra. Dabur, as per its new vision strategy, would continue to invest in core brands, would focus on premiumisation